A Phase I, First in Human Open Label Study to Evaluate the Safety and Tolerability of TRX103 Cell Infusion in Subjects with Hematological Malignancies Undergoing HLA-Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)
Use of post-transplant Cyclophosphamide (PTCy) for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) has reduced the incidence of graft versus host disease (GvHD), and expanded donor options for patients to include haploidentical and mismatched unrelated donors. Though PTCy is effective at reducing acute GvHD, 30-40% of patients receiving peripheral blood stem cell (PBSC) grafts […]
Cellular immunotherapies and immune cell depleting therapies in inflammatory bowel diseases: the next magic bullet?
Despite significant advances in biologic and small molecule treatments and the emergence of combination therapies to treat inflammatory bowel diseases (IBD) a large unmet need remains to control intestinal inflammation. New approaches targeting several pathways simultaneously with a favorable safety profile and agents that trigger anti-inflammatory pathways to drive durable resolution of inflammation are needed.
Opportunities for Treg cell therapy for the treatment of human disease
Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population can develop in the thymus and in the peripheral tissues of the immune system through the expression of an epigenetically stabilized transcription factor, FOXP3. Treg cells mediate their tolerogenic effects using multiple […]